Full history for every metric is available with a Kvantra account
Gracell Biotechnologies Inc. (GRCL)
Key financial summary
Financials in CNY| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY m | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | CNY m | -625 | -579 | |||||
| Net profit | CNY m | - | -61 | -132 | -197 | -466 | -608 | -497 |
| EPS reported | CNY | -44.85 | -35.65 | |||||
| Operating cashflow per share | CNY | -244.2 | -244.2 | |||||
| Capex per share | CNY | 24.49 | 24.49 | |||||
| FCF per share | CNY | -268.7 | -268.7 | |||||
| Free cash flow | CNY m | -3,639 | 0 | |||||
| Net debt | CNY m | -1,275 | -1,605 | |||||
| Book value equity | CNY m | 1,376 | 1,621 | |||||
| Book value per share | CNY | 101.6 | 96.58 | |||||
| Number of shares | m | 13.54 | 16.78 | |||||
| DPS (TTM paid) | CNY | 0.00 | 0.00 |
Financial summary
Financials in CNY| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.16 | 0.82 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -0.06 | -0.36 | |||||
| EV/EBITDA LTM | x | 1.86 | 0.53 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -282.83% | -65.29% | |||||
| FCF Yield | % | -1694.0% | 0.00% | |||||
| Quality | ||||||||
| ROE | % | -44.16% | -37.93% | |||||
| ROIC | % | -39.90% | -39.90% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -100.00% | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -19.89 | 0.00 | |||||
| Net Debt/EBITDA | x | 2.24 | 2.24 | |||||
| EBIT/Net interest | x | -92.72 | -92.72 | |||||
| Net debt/market cap | % | -593.69% | -120.90% | |||||
| Net debt/Equity | x | -0.93 | -0.99 | |||||
| Gross debt/equity | x | 0.13 | 0.07 | |||||
Company overview
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of cell-based therapies, primarily for cancer treatment, within the People's Republic of China. The company's leading investigational therapies include: GC012F: A FasTCAR-enhanced autologous CAR-T product designed to target both BCMA and CD19, currently undergoing Phase I clinical trials for multiple myeloma. GC019F: A FasTCAR-enabled CD19-directed autologous CAR-T therapy, which is progressing through Phase I trials for adult B-cell acute lymphoblastic leukemia (B-ALL) and is also in preclinical development for relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL). GC027: A TruUCAR-powered allogeneic CAR-T product targeting CD7, presently in Phase I clinical development for adult T-cell acute lymphoblastic leukemia. Additionally, Gracell's pipeline features: GC007g: A donor-derived allogeneic CAR-T cell therapy directed at CD19, currently in a Phase 1/2 registrational study for r/r B-ALL. GC502: An off-the-shelf, TruUCAR-enabled allogeneic CAR-T candidate engineered to target both CD19 and CD7, which is in Phase I trials for B-cell malignancies. Beyond these, Gracell maintains a broader portfolio of earlier-stage therapeutic candidates addressing diverse oncological conditions, including ovarian cancer, breast cancer, peripheral T cell lymphoma (a subtype of NHL), and T cell lymphoblastic leukemia. Established in 2017, the company's headquarters are situated in Suzhou, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Gracell Biotechnologies Inc. (GRCL)
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of cell-based therapies, primarily for cancer treatment, within the People's Republic of China. The company's leading investigational therapies include: GC012F: A FasTCAR-enhanced autologous CAR-T product designed to target both BCMA and CD19, currently undergoing Phase I clinical trials for multiple myeloma. GC019F: A FasTCAR-enabled CD19-directed autologous CAR-T therapy, which is progressing through Phase I trials for adult B-cell acute lymphoblastic leukemia (B-ALL) and is also in preclinical development for relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL). GC027: A TruUCAR-powered allogeneic CAR-T product targeting CD7, presently in Phase I clinical development for adult T-cell acute lymphoblastic leukemia. Additionally, Gracell's pipeline features: GC007g: A donor-derived allogeneic CAR-T cell therapy directed at CD19, currently in a Phase 1/2 registrational study for r/r B-ALL. GC502: An off-the-shelf, TruUCAR-enabled allogeneic CAR-T candidate engineered to target both CD19 and CD7, which is in Phase I trials for B-cell malignancies. Beyond these, Gracell maintains a broader portfolio of earlier-stage therapeutic candidates addressing diverse oncological conditions, including ovarian cancer, breast cancer, peripheral T cell lymphoma (a subtype of NHL), and T cell lymphoblastic leukemia. Established in 2017, the company's headquarters are situated in Suzhou, China.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free